Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
45 studies found for:    Open Studies | "Neuroma"
Show Display Options
Rank Status Study
21 Recruiting Preoperative Vestibular Rehabilitation Effectiveness After Vestibular Schwannoma Surgery
Condition: Vestibular Schwannoma
Intervention: Other: Preoperative vestibular rehabilitation
22 Recruiting Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.
Condition: Vestibular Schwannoma
Intervention: Radiation: gamma knife radiosurgery
23 Recruiting Gamma Knife Radiosurgery vs Initial Conservative Treatment for Vestibular Schwannoma Patients With Preserved Hearing, a Prospective Randomized Study
Condition: Vestibular Schwannoma
Intervention: Radiation: Initial Gamma knife radiosurgery
24 Recruiting Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Vestibular Schwannoma;   Neurofibromatosis Type 2
Intervention: Drug: Icotinib
25 Recruiting Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas
Intervention: Drug: Axitinib
26 Recruiting Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas;   Meningiomas
Intervention: Drug: RAD001
27 Recruiting Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
Conditions: Neurofibromatosis 2;   Vestibular Schwannoma;   Meningioma;   Ependymoma;   Glioma
Intervention: Drug: Selumetinib
28 Recruiting Familial Investigations of Childhood Cancer Predisposition
Conditions: Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
Intervention:
29 Recruiting AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Conditions: Neurofibromatosis 2;   Meningioma
Intervention: Drug: AZD2014
30 Recruiting Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
Condition: Neurofibromatosis 2
Interventions: Behavioral: Stress Management Group 1;   Behavioral: Stress Management Group 2
31 Recruiting Neurofibromatosis (NF) Registry Portal
Conditions: Neurofibromatosis 1;   Neurofibromatosis 2;   Schwannomatosis
Intervention:
32 Recruiting Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Condition: Malignant Peripheral Nerve Sheath Tumors
Intervention:
33 Recruiting Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Conditions: Metastatic Angiosarcoma;   Metastatic Epithelioid Sarcoma;   Metastatic Fibrosarcoma;   Metastatic Leiomyosarcoma;   Metastatic Liposarcoma;   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Myxofibrosarcoma;   Pleomorphic Rhabdomyosarcoma;   Stage III Soft Tissue Sarcoma;   Stage IV Soft Tissue Sarcoma;   Undifferentiated (Embryonal) Sarcoma
Interventions: Drug: Doxorubicin;   Drug: Ribociclib
34 Not yet recruiting Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors
Condition: Peripheral Nerve Tumors
Intervention: Drug: CPI-0610
35 Recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Dermoid Cyst;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
36 Recruiting Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Conditions: Metastatic Malignant Peripheral Nerve Sheath Tumor;   Neurofibromatosis Type 1;   Recurrent Malignant Peripheral Nerve Sheath Tumor
Interventions: Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter;   Other: Quality-of-Life Assessment;   Procedure: Single Photon Emission Computed Tomography
37 Recruiting A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
Condition: Malignant Peripheral Nerve Sheath Tumour (MPNST)
Intervention: Drug: Pembrolizumab
38 Recruiting Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Conditions: High Grade Sarcoma;   Metastatic Leiomyosarcoma;   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Myxofibrosarcoma;   Recurrent Leiomyosarcoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Synovial Sarcoma;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Uterine Corpus Leiomyosarcoma
Interventions: Drug: Pazopanib Hydrochloride;   Drug: Sapanisertib
39 Recruiting PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Conditions: Sarcoma;   Malignant Peripheral Nerve Sheath Tumors
Interventions: Drug: PLX3397;   Drug: Sirolimus
40 Recruiting Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Conditions: Sarcoma, Soft Tissue;   Soft Tissue Sarcoma;   Undifferentiated Pleomorphic Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Synovial Sarcoma;   Myxofibrosarcoma;   Angiosarcoma;   Fibrosarcoma;   Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma
Interventions: Drug: Dexrazoxane;   Drug: Doxorubicin;   Drug: Olaratumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-45) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.